Your unrestricted view into eyecare conferences across the spectrum. Gain exclusive access to Ophthalmology Times Europe® expert-led conference coverage from major meetings throughout the year featuring articles, videos, and insights shared by prominent experts of the ophthalmic community
Should endocyclophotocoagulation be considered part of MIGS? Mr Ratnarajan delves in
September 27th 2022Mr Gokulan Ratnarajan recaps his 2022 ESCRS presentation: "A Real World Comparison Of iStent Combined With Phacoemulsification And Endocyclophotocoagulation (Ice2) With Preserflo And Xen-45 Implants In The UK; Short- And Long-Term Outcomes."
Congress of the ESCRS reaches milestone age
September 12th 2022Taking place from 16–20 September 2022, and following the success of last year’s congress, the 40th ESCRS will again be a face-to-face event but supported by a virtual conferencing platform that will allow the sessions to also be streamed.
Positive interim data in Phase 2 BEHOLD trial investigating UBX1325 in DMO patients
September 10th 202212-week interim results of BEHOLD, a proof-of-concept Phase 2a study investigating the candidate UBX1325, provides a positive outlook for a novel senolytic approach for previously-treated patients with diabetic macular oedema.
Fluid monitor utilises AI to identify, localise and quantify retinal fluid
September 7th 2022Eyecare specialists benefit from being able to monitor their patients long term for optimised and personalised treatment regimens, as well as having access to a more efficient workflow and one which enables them to see more patients.
Multicentre Phase 3 clinical trial using AI in nAMD identifies, measures fluid volumes in real time
September 6th 2022According to Dr Gregor S. Reiter, the results from the multicentre Phase 3 clinical trial demonstrated that fluid volumes in patients with nAMD can be precisely identified, localised and measured in real-time using artificial intelligence.
First analysis of gene therapy for RPE65 inherited retinal dystrophies shows good safety, efficacy
September 3rd 2022At the 1-month evaluation, the full-field stimulus threshold had median decrease of -33.2 decibels (dB) (-33.7; -19.8) dB, which remained stable until the last assessment. Visual fields and visual acuity did not change significantly.